Biotech that bought GlaxoSmithKline's 'bubble boy' drug is building stem cell manufacturing facility in U.S.

Orchard Therapeutics will intends to build a stem cell and vector manufacturing facility in the San Francisco area. (FDA)

Another cell manufacturing facility will be built in the U.S., this one by a transatlantic biotech in which GlaxoSmithKline owns a sizable share.

The U.K.-based Orchard Therapeutics intends to spend some of the proceeds of an IPO to build a cell production facility in the San Francisco area and use the rest to take three gene therapies through the clinic and onto the market, according to a prospectus filed last week.